Cargando…
Androgen deprivation therapy plus apalutamide as neoadjuvant therapy prior radical prostatectomy for patients with unresectable prostate cancer
Whether neoadjuvant therapy confers a survival benefit in advanced prostate cancer (PCa) remains uncertain. The primary endpoints of previous retrospective and phase II clinical studies that used neoadjuvant therapy, including androgen deprivation therapy combined with new-generation androgen recept...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620516/ https://www.ncbi.nlm.nih.gov/pubmed/37927597 http://dx.doi.org/10.3389/fphar.2023.1284899 |
_version_ | 1785130223681929216 |
---|---|
author | Wei, Yongbao Zhang, Ruochen Zhong, Dewen Chen, Zhensheng Chen, Gen Yang, Minggen Lin, Le Li, Tao Ye, Liefu Chen, Lili Zhu, Qingguo |
author_facet | Wei, Yongbao Zhang, Ruochen Zhong, Dewen Chen, Zhensheng Chen, Gen Yang, Minggen Lin, Le Li, Tao Ye, Liefu Chen, Lili Zhu, Qingguo |
author_sort | Wei, Yongbao |
collection | PubMed |
description | Whether neoadjuvant therapy confers a survival benefit in advanced prostate cancer (PCa) remains uncertain. The primary endpoints of previous retrospective and phase II clinical studies that used neoadjuvant therapy, including androgen deprivation therapy combined with new-generation androgen receptor signaling inhibitors or chemotherapy, were pathological downstaging, progression-free survival, prostate-specific antigen relief, and local symptom improvement. To the best of our knowledge, no studies have explored the efficacy and safety of neoadjuvant therapy in improving the surgical resection rate in cases of unresectable primary tumors of PCa. We first designed this retrospective study to evaluate the potential value of apalutamide as neoadjuvant therapy in improving the resectability rate of radical prostatectomy (RP). We initially reported 7 patients with unresectable primary lesions who underwent neoadjuvant apalutamide treatment for a median of 4 months, and all of them successfully underwent RP treatment. Our study supported apalutamide as neoadjuvant therapy, which helped improve RP’s success rate and did not significantly increase perioperative complications, and the neoadjuvant therapy was controllable. Our findings’ clinical value and benefit for survival still need further clinical research to confirm. |
format | Online Article Text |
id | pubmed-10620516 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-106205162023-11-03 Androgen deprivation therapy plus apalutamide as neoadjuvant therapy prior radical prostatectomy for patients with unresectable prostate cancer Wei, Yongbao Zhang, Ruochen Zhong, Dewen Chen, Zhensheng Chen, Gen Yang, Minggen Lin, Le Li, Tao Ye, Liefu Chen, Lili Zhu, Qingguo Front Pharmacol Pharmacology Whether neoadjuvant therapy confers a survival benefit in advanced prostate cancer (PCa) remains uncertain. The primary endpoints of previous retrospective and phase II clinical studies that used neoadjuvant therapy, including androgen deprivation therapy combined with new-generation androgen receptor signaling inhibitors or chemotherapy, were pathological downstaging, progression-free survival, prostate-specific antigen relief, and local symptom improvement. To the best of our knowledge, no studies have explored the efficacy and safety of neoadjuvant therapy in improving the surgical resection rate in cases of unresectable primary tumors of PCa. We first designed this retrospective study to evaluate the potential value of apalutamide as neoadjuvant therapy in improving the resectability rate of radical prostatectomy (RP). We initially reported 7 patients with unresectable primary lesions who underwent neoadjuvant apalutamide treatment for a median of 4 months, and all of them successfully underwent RP treatment. Our study supported apalutamide as neoadjuvant therapy, which helped improve RP’s success rate and did not significantly increase perioperative complications, and the neoadjuvant therapy was controllable. Our findings’ clinical value and benefit for survival still need further clinical research to confirm. Frontiers Media S.A. 2023-10-19 /pmc/articles/PMC10620516/ /pubmed/37927597 http://dx.doi.org/10.3389/fphar.2023.1284899 Text en Copyright © 2023 Wei, Zhang, Zhong, Chen, Chen, Yang, Lin, Li, Ye, Chen and Zhu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Wei, Yongbao Zhang, Ruochen Zhong, Dewen Chen, Zhensheng Chen, Gen Yang, Minggen Lin, Le Li, Tao Ye, Liefu Chen, Lili Zhu, Qingguo Androgen deprivation therapy plus apalutamide as neoadjuvant therapy prior radical prostatectomy for patients with unresectable prostate cancer |
title | Androgen deprivation therapy plus apalutamide as neoadjuvant therapy prior radical prostatectomy for patients with unresectable prostate cancer |
title_full | Androgen deprivation therapy plus apalutamide as neoadjuvant therapy prior radical prostatectomy for patients with unresectable prostate cancer |
title_fullStr | Androgen deprivation therapy plus apalutamide as neoadjuvant therapy prior radical prostatectomy for patients with unresectable prostate cancer |
title_full_unstemmed | Androgen deprivation therapy plus apalutamide as neoadjuvant therapy prior radical prostatectomy for patients with unresectable prostate cancer |
title_short | Androgen deprivation therapy plus apalutamide as neoadjuvant therapy prior radical prostatectomy for patients with unresectable prostate cancer |
title_sort | androgen deprivation therapy plus apalutamide as neoadjuvant therapy prior radical prostatectomy for patients with unresectable prostate cancer |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620516/ https://www.ncbi.nlm.nih.gov/pubmed/37927597 http://dx.doi.org/10.3389/fphar.2023.1284899 |
work_keys_str_mv | AT weiyongbao androgendeprivationtherapyplusapalutamideasneoadjuvanttherapypriorradicalprostatectomyforpatientswithunresectableprostatecancer AT zhangruochen androgendeprivationtherapyplusapalutamideasneoadjuvanttherapypriorradicalprostatectomyforpatientswithunresectableprostatecancer AT zhongdewen androgendeprivationtherapyplusapalutamideasneoadjuvanttherapypriorradicalprostatectomyforpatientswithunresectableprostatecancer AT chenzhensheng androgendeprivationtherapyplusapalutamideasneoadjuvanttherapypriorradicalprostatectomyforpatientswithunresectableprostatecancer AT chengen androgendeprivationtherapyplusapalutamideasneoadjuvanttherapypriorradicalprostatectomyforpatientswithunresectableprostatecancer AT yangminggen androgendeprivationtherapyplusapalutamideasneoadjuvanttherapypriorradicalprostatectomyforpatientswithunresectableprostatecancer AT linle androgendeprivationtherapyplusapalutamideasneoadjuvanttherapypriorradicalprostatectomyforpatientswithunresectableprostatecancer AT litao androgendeprivationtherapyplusapalutamideasneoadjuvanttherapypriorradicalprostatectomyforpatientswithunresectableprostatecancer AT yeliefu androgendeprivationtherapyplusapalutamideasneoadjuvanttherapypriorradicalprostatectomyforpatientswithunresectableprostatecancer AT chenlili androgendeprivationtherapyplusapalutamideasneoadjuvanttherapypriorradicalprostatectomyforpatientswithunresectableprostatecancer AT zhuqingguo androgendeprivationtherapyplusapalutamideasneoadjuvanttherapypriorradicalprostatectomyforpatientswithunresectableprostatecancer |